40 related articles for article (PubMed ID: 8740200)
1. The attenuated inhibitory action of octreotide, a somatostatin analogue on GHRH-induced growth hormone response in type I diabetes mellitus.
Krassowski J; Rogala H; Jeske W; Zgliczynski S
Horm Metab Res; 1996 Apr; 28(4):207-8. PubMed ID: 8740200
[No Abstract] [Full Text] [Related]
2. Octreotide administration, under particular temporal conditions, enhances the responses of growth hormone to growth hormone-releasing hormone in normal subjects.
Valcavi R; Zini M
Clin Endocrinol (Oxf); 1994 Mar; 40(3):379-82. PubMed ID: 8187302
[TBL] [Abstract][Full Text] [Related]
3. [Effect of octreotide on blood glucose levels in poorly compensated insulin-dependent diabetics on insulin treatment].
Lunetta M; Di Mauro M; Le Moli R
Minerva Endocrinol; 1992; 17(1):7-12. PubMed ID: 1495454
[TBL] [Abstract][Full Text] [Related]
4. Continuous subcutaneous octreotide infusion: dose-response relationships between metabolic effects and octreotide clearance in patients with insulin-dependent (type 1) diabetes.
Osei K; O'Dorisio TM; Malarkey WB; Cataland S
J Lab Clin Med; 1991 Jul; 118(1):56-64. PubMed ID: 2066644
[TBL] [Abstract][Full Text] [Related]
5. Repeated administration of growth hormone-releasing hormone with or without previous administration of pyridostigmine in insulin-dependent diabetes mellitus.
Martina V; Bruno G; Tagliabue M; Maccario M; Bertaina S; Zumpano E; Arvat E; Ghigo E; Camanni F
Horm Metab Res; 1997 Apr; 29(4):180-3. PubMed ID: 9178028
[TBL] [Abstract][Full Text] [Related]
6. Inhibition by salbutamol of GHRH-induced GH release in type 1 diabetes mellitus.
Martina V; Miola C; Maccario M; Talliano M; Arvat E; Ghigo E; Camanni F
Horm Metab Res; 1992 Nov; 24(11):520-3. PubMed ID: 1333441
[TBL] [Abstract][Full Text] [Related]
7. Growth hormone excess and the effect of octreotide in cats with diabetes mellitus.
Slingerland LI; Voorhout G; Rijnberk A; Kooistra HS
Domest Anim Endocrinol; 2008 Nov; 35(4):352-61. PubMed ID: 18801640
[TBL] [Abstract][Full Text] [Related]
8. Insulin sensitivity test using a somatostatin analogue, octreotide (Sandostatin).
Mimura A; Kageyama S; Maruyama M; Ikeda Y; Isogai Y
Horm Metab Res; 1994 Apr; 26(4):184-7. PubMed ID: 8082872
[TBL] [Abstract][Full Text] [Related]
9. Effect of octreotide on growth hormone, IGF-I, IGFBP-3, glucagon, cortisol and epinephrine response to insulin-induced hypoglycaemia in insulin-dependent diabetic patients.
Lunetta M; Di Mauro M; Le Moli R; Nicoletti F
Diabetes Metab; 1997 Dec; 23(6):524-7. PubMed ID: 9496559
[TBL] [Abstract][Full Text] [Related]
10. [Type 2 diabetes: treatment with a somatostatin analog? Endocrine and metabolic effects in healthy probands and patients with type 2 diabetes].
Füessl HS
Fortschr Med; 1989 Aug; 107(24):509. PubMed ID: 2793029
[No Abstract] [Full Text] [Related]
11. Long-term treatment of acromegaly with Sandostatin (SMS 201-995). Normalization of most anomalous growth hormone responses.
Pieters GF; van Liessum PA; Smals AG; van Gennep JA; Benraad TJ; Kloppenborg PW
Acta Endocrinol Suppl (Copenh); 1987; 286():9-18. PubMed ID: 2892339
[TBL] [Abstract][Full Text] [Related]
12. [Role of a prolonged-action analog of somatostatin SMS 201-995 in the therapy of type 2 diabetes mellitus].
Candrina R; Giustina G
Medicina (Firenze); 1988; 8(3):313-5. PubMed ID: 3231042
[No Abstract] [Full Text] [Related]
13. [Analgesic effects of natural growth hormone release inhibitors and their synthetic analogs. Intraspinal administration].
Beltrutti D; Debernardi F; Pelosi G
Minerva Med; 1997; 88(1-2):39-47. PubMed ID: 9132630
[TBL] [Abstract][Full Text] [Related]
14. Arginine abolishes the inhibitory effect of glucose on the growth hormone response to growth hormone-releasing hormone in man.
Ghigo E; Miola C; Aimaretti G; Valente F; Procopio M; Arvat E; Yin-Zhang W; Camanni F
Metabolism; 1992 Sep; 41(9):1000-3. PubMed ID: 1355580
[TBL] [Abstract][Full Text] [Related]
15. Postprandial glycaemic effects of a long-acting somatostatin analogue (octreotide) in non-insulin dependent diabetes mellitus.
Williams G; Füessl HS; Burrin JM; Chilvers E; Bloom SR
Horm Metab Res; 1988 Mar; 20(3):168-70. PubMed ID: 2898427
[TBL] [Abstract][Full Text] [Related]
16. Improvement of diabetes after treatment with somatostatin analogue SMS 201-995 in an acromegalic patient.
Cantalamessa L; Catania A; Baldini M; Orsatti A
Horm Metab Res; 1986 Nov; 18(11):790-1. PubMed ID: 2878866
[TBL] [Abstract][Full Text] [Related]
17. Lack of pharmacological effect of subcutaneous octreotide in an insulin-dependent diabetic patient: reversal after mixing with aprotinin.
Lunetta M; Di Mauro M; Le Moli R
J Endocrinol Invest; 1997 Jun; 20(6):331-4. PubMed ID: 9294779
[TBL] [Abstract][Full Text] [Related]
18. A case of somatostatinoma: responses to food and SMS 201-995 administration.
Davis TM; Bray G; Domin J; Bloom SR
Pancreas; 1988; 3(6):729-33. PubMed ID: 2906126
[TBL] [Abstract][Full Text] [Related]
19. Acute effect of the somatostatin analogue SMS-201995 on plasma glucose and triglycerides in insulin-dependent diabetic patients.
Malerbi DA; de-Camargo JW; Cesar FP; Wajchenberg BL
Braz J Med Biol Res; 1992; 25(6):593-600. PubMed ID: 1342235
[TBL] [Abstract][Full Text] [Related]
20. Plasma growth hormone-releasing hormone levels in type 1 (insulin-dependent) diabetic children following a mixed meal.
Rosskamp R; Haverkamp F; Thomas B; Klumpp J
Klin Wochenschr; 1988 Mar; 66(6):257-60. PubMed ID: 2896808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
